Plaintiff
5 cases as plaintiff.
Astellas Pharma Inc. is a Japanese multinational pharmaceutical company headquartered in Tokyo. It was formed on April 1, 2005, through the merger of Yamanouchi Pharmaceutical, founded in 1923, and Fujisawa Pharmaceutical, founded in 1894. Astellas is a public company, trading on the Tokyo Stock Exchange under the ticker 4503. For the fiscal year ending in March 2025, the company reported revenues of approximately $12.6 billion and employs over 14,000 people globally.
Astellas is an operating company focused on the research, development, and commercialization of pharmaceutical products. The company's key therapeutic areas include oncology, urology, immunology (transplantation), ophthalmology, and women's health. Its major products include Xtandi (for prostate cancer), Padcev (for urothelial cancer), Xospata (for acute myeloid leukemia), Myrbetriq/Betanis (for overactive bladder), and Prograf (an immunosuppressant for organ transplantation). Oncology is a primary focus, with products like Xtandi, Padcev, and Xospata being significant revenue drivers.
As a research-based pharmaceutical company, Astellas actively uses patent litigation to protect its innovations. The provided case data shows the company exclusively as a plaintiff in all six tracked suits, indicating a strategy of enforcing its patent rights against competitors. All listed cases are filed in the U.S. District Court for the District of New Jersey, a common venue for pharmaceutical patent litigation. These lawsuits are typical for a brand-name drug manufacturer, often targeting companies that file Abbreviated New Drug Applications (ANDAs) seeking to market generic versions of their products. The defendants listed, such as Dr. Reddy's Laboratories, Hikma Pharmaceuticals, and Zydus Pharmaceuticals, are well-known generic drug manufacturers.
Watchlist
Email-only, free, anonymous. We'll notify you when Astellas Pharma Inc. files another patent-infringement lawsuit. One-click unsubscribe from any alert.
The claims and counterclaims in this case were dismissed with prejudice, with each party bearing its own costs.
This case has been consolidated with case 3:24-cv-09748 for all purposes. An amended complaint including the '628 patent was filed on January 3, 2025, and the case appears to be ongoing.
This case has been consolidated with case 3:24-cv-09403 and appears to be ongoing. An amended complaint including US patent 12161628 was filed on January 3, 2025.
This case is part of the broader litigation surrounding generic versions of the drug Xtandi® (enzalutamide), involving US Patent 11,839,689.
This case was mentioned in court filings for the Hikma case, but further details on the specific defendants and current status were not available in the provided narrative.